Otsuka Pharmaceutical Europe Ltd. (Otsuka) and H. Lundbeck A/S (Lundbeck) today announced that the European Commission (EC) has approved Rxulti® (brexpiprazole) for the treatment of schizophrenia in ...

The decision was supported by a randomised, six-week, placebo-controlled trial involving 316 adolescent subjects.

Otsuka Pharmaceutical Europe and Lundbeck have announced that the European Commission has approved Rxulti (brexpiprazole) for ...

The European Commission (EC) has approved Danish CNS specialist Lundbeck (LUND: CO) and Otsuka Europe’s Rxulti ...

Vadodara: Alembic Pharma has announced that the United States Food and Drug Administration (USFDA) has concluded an ...

Obesity and pharmacology experts are warning about hidden safety risks and efficacy issues for many types of medications in ...

Operator Ladies and gentlemen, thank you for standing by, and welcome to the COMPASS Pathways Limited fourth quarter 2024 investor call. [Operator instructions] I will now hand today's call over to ...

I mean, the patient population, we're also going to have a little bit of guidance of the -- from the FDA's attitude, from the AdCom that's going to take place for brexpiprazole, which we'll ...